Gastrointestinal stromal tumors–a review

Acta Orthopaedica Scandinavica

Volumn 75, Issue sup311, 2004, Pages 62-71

  Joensuu, H ^a   Kindblom, L G ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ADENOSINE TRIPHOSPHATE; BCR ABL PROTEIN; CYTOTOXIC AGENT; FLT3 LIGAND; IMATINIB; MEMBRANE PROTEIN; MIDOSTAURIN; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER RISK; CANCER SURGERY; CELL PROLIFERATION; CLINICAL FEATURE; CLINICAL TRIAL; DRUG RESPONSE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MESENCHYMOMA; ONCOGENE; PROGNOSIS; PROTEIN BINDING; PROTO ONCOGENE; REVIEW; RISK ASSESSMENT; TREATMENT FAILURE; TREATMENT OUTCOME;

CHEMOTHERAPY, ADJUVANT; GASTROINTESTINAL NEOPLASMS; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PROGNOSIS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RISK ASSESSMENT; STROMAL CELLS;

EID: 2342584093     PISSN: 00016470     EISSN: 17453682     Source Type: Journal    
DOI: 10.1080/00016470410001708340     Document Type: Article

References (56)

1. Beghini A, Tibiletti M, Roversi G, et al. Germline mutation in the juxtamembrane domain of the Kit gene in a family with gastrointestinal stromal tumors and urticaria pig-mentosa. Cancer 2001; 92: 657 – 62.
2. Benjamin RS, Rankin C, Fletcher C, et al. Phase III dose-randomized study of imatinib mesylate for GIST: Inter-group S0033 early results. Proc Am Soc Clin Oncol 2003; 22: 814. (abstract 3271)
3. Brizzi MF, Dentelli P, Rosso A, et al. STAT protein recruit-ment and activation in c-kit deletion mutants. J Biol Chem 1999; 274: 16965 – 72.
4. Broudy VC. Stem cell factor and hematopoiesis. Blood 1997; 90: 1345 – 64.
5. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100 – 4.
6. Carney JA. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc 1999; 74: 543 – 52.
7. Catena F, Pasqualine E, Campione O. Gastrointestinal stro-mal tumors: experience of an emergency surgery depart-ment. Dig Surg 2000; 17: 503 – 7.
8. Chen H, Pruitt A, Nicol TL, et al. Complete hepatic resection of metastases from leiomyosarcoma prolongs survival. J Gastrointenst Surg 1998; 2: 151 – 5.
9. Clary BM, DeMatteo, RP, Lewis JJ, et al. Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison. Ann Surg Oncol 2001; 8: 290 – 9.
10. Corless CL, McGreevey L, Haley A, et al. KIT mutations are common in incidental gastrointestinal tumors one centi-meter or less in size. Am J Pathol 2002; 160: 1567 – 72.
11. Crosby JA, Caton CN, Davis A, et al. Malignant gastroin-testinal stromal tumors of the small intestine: A review of 50 cases from a prospective database. Ann Surg Oncol 2001; 8: 50 – 9.
12. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastro-intestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51 – 8.
13. Demetri GD, George S, Heinrich MC et al. Clinical activ-ity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients with metastatic gastrointes-tinal stromal tyumor refractory to imatinib mesylate. Proc Am Soc Chin Oncol 2003; 22: 814 (abstract 3273)
14. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472 – 80.
15. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl J Med 2001; 344: 1031 – 7.
16. Druker BJ, Tamura S, Buchdunger E, et al. Effects of selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561 – 66
17. El-Rifai W, Sarlomo-Rikala M, Miettinen M, et al. DNA copy number losses in chromosome 14; an early change in gastrointestinal stromal tumors. Cancer Res 1996; 56: 3230 – 3.
18. Emory TS, Sobin LH, Lukes L, et al. Prognosis of gastro-intestinal smooth-muscle (stromal) tumors. Am J Surg Pathol 1999; 23: 82 – 7.
19. Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33: 459 – 65.
20. Fletcher JA, Corless CL, Dimitrijevic S, et al. Mechanisms of resistance to imatinib mesylate (IM) in advanced gas-trointestinal stromal tumor (GIST). Proc Am Soc Chin Oncol 2003; 22: 814. (abstract 3275)
21. Fong Y, Coit DG, Woodruff JM, et al. Lymph node metas-tasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg 1993; 217: 72 – 7.
22. Fukasawa T, Chong JM, Sakurai S, et al. Allelic loss of 14q and 22q, NF mutation, and genetic instability occur inde-pendently of c-kit mutation in gastrointestinal stromal tumor. Jpn J Cancer Res 2000; 91: 1241 – 9.
23. Gone ME, Mohammed M, Ellwood K, et al. Clinical resis-tance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876 – 80.
24. Heinrich MC, Blanke CD, Druker BJ, et al. Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies. J Chin Oncol 2002; 20: 1692 – 1703.
25. Heinrich MC, Corless CL, Demetri GD, et al. KIT and PDGFRA mutations predict imatinib mesylate response. J Clin Oncol 2003; 21: 4342 – 9.
26. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299; 708 – 10.
27. Hemesath TJ, Price ER, Takemoto C, et al. MAP kinase links the transcription factor Microphthalmia to c-kit sig-nalling in melanocytes. Nature 1998; 391: 298 – 301.
28. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577 – 80.
29. Hirota S, Ohashi A, Nishida T, Isozaki K, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003; 125; 660 – 7.
30. Joensuu H, Dimitrijevic S. Tyrosine kinase inhibitor ima-tinib (STI571) as an anticancer agent for solid tumors. Ann Med 2001; 33: 451 – 5.
31. Joensuu H, Fletcher C, Dimitrijevic S, et al. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002; 3: 655 – 64.
32. Joensuu H, Roberts P, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with meta-static gastrointestinal stromal tumor. New Engl J Med 2001; 344: 1052 – 6.
33. Karakousis CP, Blumenson LE, Canavase G, et al. Surgery for disseminated abdominal sarcoma. Am J Surg 1992; 163: 560 – 4.
34. Kindblom L-G, Meis-Kindblom JM, Bumming P, et al. Incidence, prevalence, phenotypic and biologic spectrum of gastrointestinal stromal tumors (GIST)-a population based study of 600 cases. Ann Oncol 2002; 13 suppl 5. (abstract 5770)
35. Kindblom L-G, Remotti HE, Aldenborg F, et al. Gastroin-testinal pacemaker cell tumor (GIPACT). Gastrointestinal stromal tumors show phenotypic characteristics of the intestinal cells of Cajal. Am J Pathol 1998; 152: 1259 – 69.
36. Kinoshita K, Hirota S, Isozaki K, et al. Absence of c-kit gene mutations in gastrointestinal stromal tumours from neuro-fibromatosis 1 patients. J Pathol 2004; 202: 80 – 5.
37. Maeyama H, Hidaka E, Ota H, et al. Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 2001; 120: 210 – 5.
38. Mazur MT, Clark HB. Gastric stromal tumors: Reappraisal of histogenesis. Am J Surg Pathol 1983; 7: 507 – 19.
39. Miettinen M, Lasota J. Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1 – 12.
40. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumours: Recent advances in understanding of their biology. Hum Pathol 1999; 30: 1213 – 20.
41. Ng E-H, Pollock RE, Munsell MF, et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Ann Surg 1992; 215: 68 – 77.
42. Nishida T, Hirota S. Biological and clinical review of stro-mal tumors in the gastrointestinal tract. Histol Histopathol 2000; 15: 1293 – 1301.
43. Nishida T, Hirota S, Taniguchi M, et al. Familial gastrointes-tinal stromal tumours with germline mutation of the KIT gene. Nature Genet 1998; 19: 323 – 4.
44. Pidhorecky I, Cheney RT, Kraybill WG, et al. Gastrointesti-nal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol 2000; 7: 705 – 12.
45. Plaat BEC, Hollema H, Molenaar WM, et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000; 18: 3211 – 20.
46. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiq-uitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61: 8118 – 21.
47. Rudolph P, Gloeckner K, Parwaresch R, et al. Immunophe-notype, proliferation, DNA ploidy, and biological behav-ior of gastrointestinal stromal tumors: A multivariate clinicopathologic study. Hum Pathol 1998; 29: 791 – 800.
48. Sakurai S, Hishima T, Takazawa Y, et al. Gastrointestinal stromal tumors and KIT-positive mesenchymal cells in the omentum. Pathol hit 2001; 51: 524 – 31.
49. Strickland L, Letson GD, Muro-Cacho CA. Gastrointestinal stromal tumors. Cancer Control 2001; 8: 252 – 61.
50. Tsuura Y, Hiraki H, Watanabe K, et al. Preferential localiza-tion of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma, and seminoma/dysgermnoma in humans: Immunohis-tochemical study of formalin-fixed, paraffin-embedded tissues. Virchows Arch 1994; 424: 135 – 41.
51. Van den Abbeele AD. F18-FDG-PET provides early evi-dence of biological response to STI571 in patients with malignant gastrointestinal stromal tumors (GIST). Proc Am Assoc Clin Oncol 2001; 20: 362a. (abstract)
52. Vanderwinden JM, Rumessen JJ, De Laet MH, et al. CD34 immunoreactivity and interstitial cells of Cajal in the human and mouse gastrointestinal tract. Cell Tissue Res 2000; 302: 145 – 53.
53. Van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointesti-nal stromal tumours: a phase I study. Lancet 2001; 358: 1421 – 3.
54. Verweij J, Casali PG, Zalcberg J, et al. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): Interim results of a randomized phase ifi trial from the EORTC-STBSG, ISG and AGITG. Proc Am Soc Chin Oncol 2003; 22: 814. (abstract 3272)
55. Weiler SR, Mou S, DeBerry CS, et al. JAK2 is associated with the c-kit proto-oncogene product and is phosphory-lated in response to stem cell factor. Blood 1996; 87: 3688 – 93.
56. Yarden Y, Kuang WJ, Yang-Feng T, et al. Human proto-onco-gene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1988; 6: 3341 – 51.